Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease

Nephron - Clinical Practice

Volumn 97, Issue 2, 2004, Pages

  Weinstein, Talia ^a   Chagnac, Avry ^a   Boaz, Mona ^b   Ori, Yaacov ^a   Herman, Michal ^a   Zevin, Dina ^a   Schmilovitz Weiss, Hemda ^a   Gafter, Uzi ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Dialysis; HBV; Immunogenicity; Vaccine

Indexed keywords

ALBUMIN; BIO HEP; ENGERIX; HEMOGLOBIN; HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ADULT; AGE; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; DRUG RESPONSE; FEMALE; GENDER; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; KIDNEY FAILURE; MALE; MEASUREMENT; PATIENT; PRIORITY JOURNAL; PROTECTION; RETROSPECTIVE STUDY; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 3042634757     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078403     Document Type: Article

References (29)

1. London WT, Drew JS, Lustbader ED, Werner BG, Blumberg BS: Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int 1977;12:51-58.
2. Snydman DR, Bregman D, Bryan JA: Hemodialysis-associated hepatitis in the United States. J Infect Dis 1977;135:687-691.
3. Ribot S: Duration of hepatitis B surface anti-genemia (HBsAg) in hemodialysis patients. Arch Intern Med 1979;139:178-180.
4. Tokars JI, Miller ER, Alter MJ, Arduino MJ: National surveillance of dialysis-associated diseases in the United States, 1996. Atlanta, GA, Centers for Disease Control and Prevention, 1998, pp 1-59.
5. Centers for Disease Control: Control measures for hepatitis B in dialysis centers. Viral Hepatitis Investigations and Control Series. Atlanta, GA, Centers for Disease Control and Prevention, 1977.
6. Miller ER, Alter MJ, Tokars JI: Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999;33:356-360.
7. Kurz P, Kohler H, Meuer S, Hutteroth TH, Meyer-zum-Buschenfelde KH: Impaired cellular immune responses in chronic renal failure: Evidence of a T cell defect. Kidney Int 1986;29:1209-1214.
8. Kohler H, Arnold W, Renschin G, Dormeyer HH, Meyer-zum-Buschenfelde KH: Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984;25:124-128.
9. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W: Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med 1984;311:496-501.
10. West DJ, Calandra GB, Ellis RW: Vaccination of infants and children against hepatitis B. Pediatr Clin North Am 1990;37:585-601.
11. Andre FE, Safary A: Summary of clinical findings on Engerix-B, or genetically engineered yeast-derived hepatitis B vaccine. Postgrad Med J 1987;63(suppl 2):169-178.
12. Shouval D, Ilan Y, Adler R, et al: Improved immunogenicity in mice of a mammalian cellderived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 1994;12:1453-1454.
13. Haubitz M, Ehlerding G, Beigel A, Heuer U, Hemmerling AE, Thoma HA: Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. Clin Nephrol 1996;45:180-182.
14. Yerushalmi B, Raz R, Blondheim O, Shumov E, Koren R, Dagan R: Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. Pediatr Infect Dis J 1997;16:587-592.
15. Raz R, Dagan R, Gallil A, Brill G, Kassis I, Koren R: Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. Vaccine 1996;14:207-211.
16. Hourvitz A, Mosseri R, Solomon A, et al: Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre-S antigens: A preliminary report. J Viral Hepat 1996;3:37-42.
17. Heermann N, Goldmann U, Schwartz W, Seytfarth T, Baumgarten H, Gerlich WH: Large surface proteins of hepatitis B virus containing the Pre-S sequence. J Virol 1984;52:396-402.
18. Milich DR, Thornton GB, Neurath AR, Michel ML, Tiollais P: Enhanced immunogenicity of the Pre-S region of HBV surface antigen. Science 1985;228:1195-1199.
19. Milich DR, McNamara MK, McLachlan A, Thornton GB, Chisari FU: Distinct H-2-linked regulation of T-cell dependent responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of non-responsiveness to the S region. Proc Natl Acad Sci USA 1985;82:8168-8172.
20. Gerlich W, Deepen R, Heerman KH, et al: Protective prevention of hepatitis B virus antigens other than the S gene protein. Vaccine 1990;8:563-568.
21. Neurath AR, Kent SBH, Strick N, Taylor P, Stevens CE: Hepatitis B contains Pre-S geneencoded domains. Nature 1985;315:154-156.
22. Chatenoud L, Dugas B, Beaurain G, et al: Presence of preactivated T cells in hemodialysis patients: Their possible role in altered immunity. Proc Natl Acad Sci USA 1988;83:7457-7461.
23. Descamps-Latscha B, Herbelin A: Long-term dialysis and cellular immunity: A critical survey. Kidney Int 1993;43(suppl 4):S135-S142.
24. Charest AF, McDougall J, Goldstein MB: A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000;36:976-982.
25. Rangel MC, Coronado VG, Euler GL, Strikas RA: Vaccine recommendations for patients on chronic dialysis. Semin Dial 2000;13:101-107.
26. Waite NM, Thomson LG, Goldstein MB: Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously non-responsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol 1995;5:1930-1934.
27. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F: Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: A prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997;12:1204-1211.
28. Propst T, Propst A, Lhotta K, Vogel W, Konig P: Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998;32:1041-1045.
29. Jungers P, Chaveau P, Courouc AM, et al: Immunogenicity of the recombinant GenHeval B Pasteur vaccine against hepatitis B in chronic uremic patients. J Infect Dis 1994;169:399-402.